事件 4 月 28 日公司发布 2024 年报及 2025 年一季报，2024 年实现营收 30.27 亿元，同比-24.09%；归母净利润为-2.87 亿元，同比亏损。 4Q24 收入为 10.75 亿元，环比+34.65%、同比+21.83%；归母净利 润为-0.84 亿元，环比、同比亏损。1Q25 实现收入 7.28 亿元，环 比-32.28%、同比+141.32%；归母净利润为 0.73 亿元，环比、同 比均扭亏。 点评 价格上涨，1Q25 业绩符合预期。1Q25 氧化镨钕、氧化镝、氧化铽 价格环比分别+3.29%/-0.86%/+6.79%,公司主营产品价格整体上 行；销量方面，2024 年公司稀土氧化物生产量较上年同期提升 107.27%；基于公司现有产能释放情况，我们认为 1Q25 公司产品 销量同比有所增长。1Q25 公司毛利、毛利率分别同比+446.15%、 +5.45pct 至 0.71 亿元、9.75%。 期间费率保持平稳，研发保持高投入。1Q25 公司期间费用环比 -31.91%至 0.32 亿元;期间费率环比+0.02pct 至 4.40%、同比 -2.89pct 至 4.40% ； ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5]. Core Insights - The company's FY24 revenue was 1.44 billion RMB, a year-over-year decrease of 2.78%, while Q4 2024 revenue showed a slight increase of 0.43% year-over-year [2]. - The company reported a net loss of 163 million RMB for FY24, primarily due to a goodwill impairment of 59.06 million RMB [2]. - The gross margin for FY24 was 93.22%, reflecting a decrease of 1.58 percentage points year-over-year, attributed to rising costs of AI servers [2]. - The company has seen a gradual recovery in revenue since Q3 2024, with Q1 2025 revenue increasing by 6.06% year-over-year [2]. Revenue Breakdown - Video creative products generated 961 million RMB in revenue, a slight increase of 0.06% year-over-year, accounting for 66.76% of total revenue [3]. - Practical tools revenue decreased by 8.70% year-over-year to 234 million RMB, while document creative products and drawing creative products also saw declines of 10.13% and 5.88%, respectively [3]. - International revenue accounted for 90.51% of total revenue, totaling 1.30 billion RMB, with a year-over-year decrease of 3.51% [3]. Expense Analysis - R&D, sales, and management expense ratios for FY24 were 30.72%, 58.94%, and 11.40%, respectively, with significant increases in sales expenses [4]. - In Q1 2025, the R&D expense ratio decreased to 27.79%, while the sales expense ratio increased to 62.78% [4]. - The company reported AI-related revenue of 67 million RMB in FY24, doubling year-over-year, and has integrated AI tools to enhance productivity [4]. Profit Forecast and Valuation - Revenue projections for 2025 to 2027 are set at 1.68 billion RMB, 1.97 billion RMB, and 2.36 billion RMB, respectively, with net profit estimates of 1 million RMB, 175 million RMB, and 218 million RMB [5]. - The current stock price corresponds to a price-to-sales (P/S) ratio of approximately 6.3, 5.4, and 4.5 for the years 2025 to 2027 [5].

Investment Rating - The report maintains a "Buy" rating for the company, with expected revenue growth and profitability improvements in the coming years [5]. Core Views - The company reported a revenue of 1.44 billion RMB for FY24, a year-over-year decrease of 2.78%, but showed signs of recovery with a 6.06% increase in Q1 2025 [2]. - The net profit for FY24 was a loss of 163 million RMB, primarily due to goodwill impairment of 59.06 million RMB, indicating challenges in profitability [2]. - The gross margin for FY24 was 93.22%, slightly down from the previous year, attributed to rising costs in AI server operations [2]. Revenue and Profit Analysis - FY24 revenue breakdown shows video creative products generated 961 million RMB, a slight increase of 0.06%, while practical tools and document creative categories saw declines of 8.70% and 10.13% respectively [3]. - International revenue accounted for 90.51% of total revenue, amounting to 1.30 billion RMB, with a year-over-year decrease of 3.51% [3]. Expense Structure - The company increased its R&D, sales, and management expense ratios to 30.72%, 58.94%, and 11.40% respectively in FY24, indicating a strategic focus on growth despite the losses [4]. - In Q1 2025, the sales expense ratio rose significantly to 62.78%, reflecting increased investment in sales efforts [4]. Future Projections - Revenue forecasts for 2025 to 2027 are set at 1.68 billion RMB, 1.97 billion RMB, and 2.36 billion RMB respectively, with expected net profits turning positive in 2025 [5]. - The projected price-to-sales (P/S) ratios for the next three years are approximately 6.3, 5.4, and 4.5 times, indicating a favorable valuation trend [5].

事件 4 月 28 日公司发布 2024 年报及 2025 年一季报，2024 年实现营收 30.27 亿元，同比-24.09%；归母净利润为-2.87 亿元，同比亏损。 4Q24 收入为 10.75 亿元，环比+34.65%、同比+21.83%；归母净利 润为-0.84 亿元，环比、同比亏损。1Q25 实现收入 7.28 亿元，环 比-32.28%、同比+141.32%；归母净利润为 0.73 亿元，环比、同 比均扭亏。 点评 价格上涨，1Q25 业绩符合预期。1Q25 氧化镨钕、氧化镝、氧化铽 价格环比分别+3.29%/-0.86%/+6.79%,公司主营产品价格整体上 行；销量方面，2024 年公司稀土氧化物生产量较上年同期提升 107.27%；基于公司现有产能释放情况，我们认为 1Q25 公司产品 销量同比有所增长。1Q25 公司毛利、毛利率分别同比+446.15%、 +5.45pct 至 0.71 亿元、9.75%。 期间费率保持平稳，研发保持高投入。1Q25 公司期间费用环比 -31.91%至 0.32 亿元;期间费率环比+0.02pct 至 4.40%、同比 -2.89pct 至 4.40% ； ...

事件 4 月 27 日公司发布 2025 年一季报，实现营收 17.54 亿元，环比 +0.29%、同比+14.19%；归母净利润为 1.61 亿元，环比+70.48%、 同比+57.85%；扣非归母净利润为 1.06 亿元，环比+30.70%、同比 +331.10%。 点评 量价齐升，业绩超预期。1Q25 氧化镨钕和钕铁硼市场均价分别环 比+3.29%、+1.60%至 42.96 万元/吨和 201 元/公斤；销量显著增 长，1Q25 公司磁材成品产量约 0.66 万吨，磁材成品销量约 0.6 万 吨，较上年同期均增长超 40%。量价齐升带来盈利能力显著改 善,1Q25 公司毛利率环比+1.44pct 至 15.68%，毛利环比+10.44%至 2.75 亿元。考虑公司生产经营的季节性，1Q25 业绩超预期。 整体费用控制良好，研发费用保持增长。1Q25 公司期间费用环比 -10.97% 至 1.38 亿 元 ，期间费率分别环比、同比 - 0.99pct/+0.58pct；其中销售费率环比-0.40pct 至 1.03%,财务费 率环比+0.06pct 至-0.68%。公司仍然保持高水平研发投入，1Q25 ...

业绩简评 2025 年 4 月 27 日公司披露 24 年报，24 年实现营收 12.22 亿元， 同比增长 20.98%，市场份额稳居本土 EDA 企业首位；归母净利润 1.09 亿元，同比下降 45.46%；扣非归母净利润亏损 0.57 亿元。 单 Q4 公司实现营收 4.79 亿元，同比增长 29.13%；实现归母净利 润 0.51 亿元，同比增长 73.71%。 经营分析 分业务来看，24 年公司 EDA 软件销售营收为 10.92 亿元，同比增 长 20.71%；技术服务业务营收为 1.15 亿元，同比增长 40.01%； 硬件、代理软件销售及其他收入 0.15 亿元，同比下降 35.71%。公 司境外收入占比为 4.72%，收入同比下降 13.32%。 成本费用方面，24 年公司毛利率为 93.31%，较上年同期下降 0.48pct。公司剔除股份支付费用后的销售/管理/研发费用率分别 为 16.31%/12.05%/60.79% ， 分 别 同 比 下 降 0.03pct/0.57pct/6.61pct。截至 24 年末公司共有员工 1,202 人， 同比增加 17.50%，其中销售/技术人员同比 ...

业绩简评 2025 年 4 月 25 日公司披露 24 年年报及 25 年一季报，2024 年公 司实现营收 272 亿元，同比下降 3.4%；实现归母净利润 3.46 亿 元，同比下降 8.1%。2025 年一季度公司实现收入 77.0 亿元，同 比增长 51.8%，实现归母净利润 3.0 亿元，同比下降 0.7%。 经营分析 风机制造及发电业务盈利承压，电站销售转让保持增长：2024 年 公司风机及相关配件销售实现收入 208.3 亿元，同比下降 12.4%， 实现毛利率-0.46%，同比下降 3.6%，预计主要受海风推进受阻， 交付不及预期影响，2025 年公司前期中标的广东多个重要海风项 目陆续开始施工，项目确收有望逐步加速。发电收入同比增长 15.4%，但毛利率同比下降 5.86pct 至 57.1%，预计主要受部分地 区新能源市场化交易推进，上网电价有一定下降影响。电站销售转 让保持增长，2024 年公司电站产品销售实现收入约 27.9 亿元，同 比+34.2%，毛利率同比提升 12.2pct 至 43.2%，同时实现投资收益 11.6 亿元，同比提升 38%。 Q1 交付加速，规模效应体现明显： ...

业绩简评 2025 年 4 月 27 日公司披露 24 年报，24 年实现营收 12.22 亿元， 同比增长 20.98%，市场份额稳居本土 EDA 企业首位；归母净利润 1.09 亿元，同比下降 45.46%；扣非归母净利润亏损 0.57 亿元。 单 Q4 公司实现营收 4.79 亿元，同比增长 29.13%；实现归母净利 润 0.51 亿元，同比增长 73.71%。 分业务来看，24 年公司 EDA 软件销售营收为 10.92 亿元，同比增 长 20.71%；技术服务业务营收为 1.15 亿元，同比增长 40.01%； 硬件、代理软件销售及其他收入 0.15 亿元，同比下降 35.71%。公 司境外收入占比为 4.72%，收入同比下降 13.32%。 成本费用方面，24 年公司毛利率为 93.31%，较上年同期下降 0.48pct。公司剔除股份支付费用后的销售/管理/研发费用率分别 为 16.31%/12.05%/60.79% ， 分 别 同 比 下 降 0.03pct/0.57pct/6.61pct。截至 24 年末公司共有员工 1,202 人， 同比增加 17.50%，其中销售/技术人员同比增长 17 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenue reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is projected to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenues reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is forecasted to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].